Diseases / Sarcopenia
Sarcopenia
DiseaseSarcopenia is an age-related loss of muscle mass and strength that can impair daily function and increase risks such as falls and injuries. It is recognized as a diagnosable disease entity in ICD-10-CM.
- Trials
- 1268
- Recruiting
- 193
- Completed
- 595
- With results
- 54
Last revised
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Suspended | Unknown | Temporarily not available | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | — | 2 | — | — | 5 | — | 1 | — | 1 | — | 9 |
| Phase 1 | — | — | — | — | 11 | — | — | — | — | — | 11 |
| Phase 1/2 | 1 | 2 | — | — | 5 | — | 1 | — | — | — | 9 |
| Phase 2 | 8 | 3 | — | — | 18 | 2 | — | — | 3 | — | 34 |
| Phase 2/3 | — | — | — | — | 3 | — | — | — | — | — | 3 |
| Phase 3 | 4 | 1 | 1 | — | 10 | 1 | 1 | — | 3 | — | 21 |
| Phase 4 | 2 | 1 | — | 2 | 8 | 2 | 1 | — | 4 | — | 20 |
| Not applicable | 103 | 60 | 6 | 29 | 346 | 23 | 10 | 2 | 145 | — | 724 |
| Unknown | 75 | 41 | 9 | 22 | 189 | 6 | 3 | 1 | 90 | 1 | 437 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Sarcopenia | 9 | 11 | 9 | 34 | 3 | 21 | 20 | 724 | 437 | 1268 |
| Frailty | 1 | 1 | 2 | 7 | — | 3 | 2 | 89 | 56 | 161 |
| Motor Activity | — | 2 | — | 1 | — | 3 | 1 | 121 | 11 | 139 |
| Malnutrition | — | — | — | — | — | 3 | 1 | 31 | 43 | 78 |
| Obesity | 1 | — | 1 | 4 | — | 2 | 1 | 32 | 37 | 78 |
| Osteoporosis | — | — | 1 | 2 | — | 3 | 1 | 33 | 23 | 63 |
| Muscular Atrophy | — | — | 1 | 5 | — | 1 | — | 39 | 14 | 60 |
| Neoplasms | — | — | 1 | 1 | — | — | — | 22 | 21 | 45 |
| Muscle Weakness | — | — | 1 | 2 | — | 1 | 1 | 13 | 13 | 31 |
| Liver Cirrhosis | 1 | — | — | 2 | 1 | 1 | — | 14 | 8 | 27 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | National Taiwan University Hospital | 22 | 0 |
| 2 | Maastricht University Medical Center | 17 | 0 |
| 3 | University of Nottingham | 14 | 1 |
| 4 | Chang Gung Memorial Hospital | 13 | 0 |
| 5 | Bispebjerg Hospital | 12 | 0 |
| 6 | University Hospital, Clermont-Ferrand | 12 | 0 |
| 7 | The University of Texas Medical Branch, Galveston | 10 | 0 |
| 8 | Istanbul Physical Medicine Rehabilitation Training and Research Hospital | 9 | 0 |
| 9 | McMaster University | 9 | 0 |
| 10 | Tufts University | 9 | 0 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | Exercise | 78 |
| 2 | Resistance Training | 68 |
| 3 | Absorptiometry, Photon | 14 |
| 4 | Dietary Supplements | 14 |
| 5 | Whey Proteins | 14 |
| 6 | maltodextrin | 13 |
| 7 | Proteins | 12 |
| 8 | Hand Strength | 11 |
| 9 | Cholecalciferol | 10 |
| 10 | Control Groups | 10 |
Evidence
- Results reported
- 9.1%54 of 595 completed
- Published
- 16.3%97 of 595 completed
- Primary endpoint met
- 10.3%8 of 78 analyses
- Median months to report
- 16.5
Documents disclosed
Trial profile
- Median enrollment
- 80
- Median duration
- 20months
- Countries
- 57
- Study sites
- 1559
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 22
- Phase 1
- 59
- Phase 1/2
- 26
- Phase 2
- 80
- Phase 2/3
- 80
- Phase 3
- 86
- Phase 4
- 105
- Not applicable
- 60
- Unknown
- 120
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Istanbul | Turkey (Türkiye) | 44 |
| 2 | Taipei | Taiwan | 32 |
| 3 | Ankara | Turkey (Türkiye) | 28 |
| 4 | Boston | United States | 20 |
| 5 | Seoul | South Korea | 18 |
| 6 | Maastricht | Netherlands | 16 |
| 7 | Baltimore | United States | 15 |
| 8 | Copenhagen | Denmark | 15 |
| 9 | Barcelona | Spain | 14 |
| 10 | Clermont-Ferrand | France | 14 |
Terminations
- Terminated
- 34
- Withdrawn
- 17
- Suspended
- 3
- Stopped for recruitment
- 1%13 of 1268 trials
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT06231069 Withdrawn | Withdrawn | COVID 19: Study halted prior to enrollment of first participant. | 2030-12-15 |
| NCT05060380 Withdrawn | Withdrawn | The study was never started. | 2028-12-01 |
| NCT07601321 Withdrawn | Withdrawn | The study was withdrawn before enrollment because the planned community health service center did not approve the implementation of the intervention, and no participants had been recruited. | 2026-12-31 |
| NCT06077734 Terminated | Terminated | This study was terminated prior to its planned completion due to unexpected low participant inclusion. | 2026-02-16 |
| NCT05853874 Withdrawn | Withdrawn | The RCT phase was not started due to delays in obtaining the approval by the reference Ethics Committees, logistical difficulties in starting recruitment, and low number of eligible participants. | 2026-01-31 |
| NCT03676478 Terminated | Terminated | halted prematurely on the occasion of a planned sample size reestimation after 200 randomised patients during which an unexpected futility finding was demonstrated | 2025-12-02 |
| NCT04469504 Terminated | Terminated | The study was terminated prematurely due to patient inclusion difficulties. | 2025-06-17 |
| NCT04999488 Withdrawn | Withdrawn | Drug manufacturing update. Study site will proceed with study in future. | 2024-12-31 |
| NCT03266575 Terminated | Terminated | difficulty recruiting | 2024-12-09 |
| NCT06788236 Terminated | Terminated | Due subject enrollment delay and to secure expiration of the test drug, it was necessary to minimize the subject enrollment period. In addition, it was deemed advantageous to increase the overall efficiency of the clinical program. | 2024-09-19 |
Trial records
Individual study records live on ClinicalTrials.gov. A sample of the trials counted above: